

THE ASPEN RETINAL DETACHMENT SOCIETY

"Oh vitreous where is thy humor"

33rd
Annual
Aspen Retinal
Detachment Society
Meeting

March 6–10, 2005

Snowmass Conference Center

Snowmass Village, Colorado

TIMOTHY G. MURRAY, MD

Program Chairman

JOINTLY SPONSORED BY

Aspen Retinal Detachment Society and

Spokane County Medical Society

33rd Annual Meeting Program

Sunday, March 6

3:00-5:30 pm

Meeting Registration
NASTAR Ski Race &
Picnic Lunch Registration
Welcome Reception
Snowmass Conference Center
Hoaglund Room

5:30-6:00

Van departure from
Snowmass Conference Center
to Crystal Palace

6:45-9:45

Evening at the Crystal Palace

9:45

Vans return to Snowmass Village

Monday, March 7

12:00-1:30 pm

Information discussion groups
at Sam's Knob

3:00-3:45

Exhibits/Après ski refreshments

3:45-4:10

New Thinking on the Pathogenesis
of Choroidal Neovascularization:
A Genetics Based Approach
Mark S. Blumenkranz, MD

4:10-4:20

Open discussion

4:20-4:45

Neuro-ophthalmologic
Retina 2005
William F. Hoyt, MD

4:45-4:55

Open discussion

4:55-5:20

A Prospective Randomized
Controlled Trial of a Sustained
Release Bioerodable
Dexamethasone Intravitreal
Implant for Persistent
Macular Edema
Julia A. Haller, MD

5:20-5:30

Open discussion

5:30-5:55

Refreshment break/Exhibits

5:55-6:20

Results of the Celebrex-
PDT Treatment Trial for
Neovascular AMD
David Callanan, MD

6:20-6:30

Open discussion

6:30-6:55

Anti-VEGF Therapies for AMD:
Monotherapy and Combination
Treatment Update
Allan C. Ho, MD

6:55-7:15

Open discussion

Tuesday, March 8

12:00-1:30 pm

Information discussion groups
at Sam's Knob

3:00-3:45

Exhibits/Après ski refreshments

3:45-4:10

Endophthalmitis Update
Harry W. Flynn, Jr., MD

4:10-4:20

Open discussion

4:20-4:45

Pros and Cons of
25 Gauge Vitrectomy
Virgilio Morales-Canton, MD

4:45-4:55

Open discussion

4:55-5:20

Contemporary Pediatric
Vitreoretinal Surgery:
What's Hot and Why
Antonio Capone, Jr., MD

5:20-5:30

Open discussion

5:30-5:55

Refreshment break/Exhibits

5:55-6:20

The Impact of OCT on
Surgical Decision-making
Julia A. Haller, MD

6:20-6:30

Open discussion

6:30-6:55

Update on Prevention
Therapies for AMD:
Anecortave Acetate and More
Allan C. Ho, MD

6:55-7:15

Open discussion

Wednesday, March 9

12:00 noon

NASTAR race at the Spider
Sabich Race Arena followed by
picnic at the Spider Sabich
Picnic Cabin. Racers and non-
racers are invited. Picnic will
be held if races are cancelled.
Check for location of picnic in
case of race cancellation.

3:00-3:45 pm

Exhibits/Après ski refreshments

3:45-4:10

Histopathology of Age-related Macular Degeneration
Sander R. Dubovy, MD

4:10-4:20

Open discussion

4:20-4:45

Subfoveal Hard Exudate Removal by Vitrectomy, Subretinal BSS Injection, ILM Peeling and Intravitreal Kenalog Injection in Severe Diabetic Macular Edema
Virgilio Morales-Canton, MD

4:45-4:55

Open discussion

4:55-5:20

Pharmacologic Therapy for CNV: New Prospects
Mark S. Blumenkranz, MD

5:20-5:30

Open discussion

5:30-5:55

Refreshment break/Exhibits

5:55-6:20

Retained Lens Fragment after Phacoemulsification
Harry W. Flynn, Jr., MD

6:20-6:30

Open discussion

6:30-6:55

Update on Intraocular Lymphoma
David Callanan, MD

6:55-7:15

Open discussion

Thursday, March 10

12:00-1:30 pm

Information discussion groups at Sam's Knob

3:00-3:45pm

Exhibits/Après ski refreshments

3:45-4:10

Advances in Management for Pediatric Retinoblastoma
Timothy G. Murray, MD

4:10-4:20

Open discussion

4:20-4:45

Screening for ROP – Potential Solutions to Medicolegal Challenges
Antonio Capone, Jr., MD

4:45-4:55

Open discussion

4:55-5:20

Uveal Melanoma Classification System
Sander R. Dubovy, MD

5:20-5:30

Open discussion

5:30-5:55

Refreshment break/Exhibits

5:55-6:20

Advances in Management for Malignant Melanoma
Timothy G. Murray, MD

6:20-6:30

Open discussion

6:30-7:00

THE TAYLOR SMITH LECTURE

Bradyopsia and Other Newly Recognized Forms of Retinal Dysfunction
Thaddeus P. Dryja, MD

7:00-7:15

Open discussion

7:30

Closing Dinner with presentation of NASTAR ski prizes at The El Dorado Ballroom at the Silvertree Hotel.

Speakers

Mark S. Blumenkranz, MD
Stanford University School of Medicine

David Callanan, MD
Texas Retina Associates

Antonio Capone, Jr., MD
Associated Retinal Consultants

Thaddeus P. Dryja, MD
Massachusetts Eye & Ear Infirmary
Ophthalmic Genetics Institute

Sander R. Dubovy, MD
Bascom Palmer Eye Institute

Harry W. Flynn, Jr., MD
Bascom Palmer Eye Institute

Julia A. Haller, MD
Johns Hopkins Hospital
Wilmer Eye Institute

Allen C. Ho, MD
Wills Eye Hospital

William F. Hoyt, MD
University of California at San Francisco

Virgilio Morales-Canton, MD
Hospital Asociacion Para Evitar La Ceguera

Timothy G. Murray, MD
Bascom Palmer Eye Institute

Corporate Support

The Aspen Retinal Detachment Society gratefully acknowledges the following companies for their support.

HIGHLANDS LEVEL

Alcon Laboratories, Inc.

Eyeteq Pharmaceuticals/
Pfizer Ophthalmics

Genentech, Inc

Novartis Ophthalmics

AJAX LEVEL

Bausch & Lomb

Carl Zeiss

Dutch Ophthalmic, USA

Innovative Imaging, Inc.

Insight Instruments, Inc.

MedOne Surgical, Inc.

Synergetics, Inc.

Emeritus Faculty

Robert J. Brockhurst, MD
Ariah Schwartz, MD
Morton Rosenthal, MD
William F. Hoyt, MD
William H. Spencer, MD
David O. Jesberg, MD
Paul Wetzig, MD
Victor Curtin, MD
William S. Tasman, MD
Mackenzie Freeman, MD
Morton S. Cox, MD
Conor O'Malley, MD
Robert Machemer, MD
Evangelos S. Gragoudas, MD
Jay L. Federman, MD
Ottiwel W. Jones, MD
Mary Lou Lewis, MD
Thomas F. Minas, MD
Stephen J. Ryan, MD
George Blankenship, MD
William L. Hutton, MD
C.P. Wilkinson, MD
Thomas M. Aaberg, Sr., MD
Ronald G. Michels, MD
John G. Clarkson, MD
Steve Charles, MD
Bert M. Glaser, MD
Mark S. Blumenkranz, MD
Maurice B. Landers, III, MD
John Heckenlively, MD
Ian Constable, MD
John Lean, MD
James Cairns, MD
Harry W. Flynn, Jr., MD
Donald J. D'Amico, MD
John Gregory-Roberts, MD
Brooks Crawford, MD
David W. Parke, II, MD
Wichard van Heuven, MD
Justin Playfair, MD
Jerry A. Shields, MD
Carol L. Shields, MD
William E. Smiddy, MD
Nick J. McLane, MD
Brian Conway, MD
Yale L. Fisher, MD
Rand Spencer, MD
Jerry E. LeClaire, MD
Eugene de Juan, MD

Mark S. Humayun, MD, PhD
Yasuo Tano, MD
Timothy G. Murray, MD
Joan W. Miller, MD
Janet L. Davis, MD
Daniel M. Schwartz, MD
Dennis B. Freilich, MD
William O. Edward, MD
Thomas A. Ciulla, MD
Dean Elliott, MD
Tarek S. Hassan, MD
Carmen A. Puliafito, MD, MBA
Carl D. Regillo, MD
Steven D. Schwartz, MD
Giovanni Staurengi, MD
Baruch D. Kuppermann, MD, PhD

CME Credit

This activity has been planned and implemented in accordance with the Essentials and Standards of the Washington State Medical Association (WSMA) CME Accreditation Committee through the partnership of the Spokane County Medical Society (SCMS) and the Aspen Retinal Detachment Society. The SCMS, a WSMA accredited sponsor, designates this educational activity for a maximum number of 14 hours (14.0) of Category I to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission and the American Medical Association Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.



MEDICAL CONFERENCE PLANNERS, INC.

1251 Post Road, Scarsdale, NY 10583
914-722-0664 phone
914-722-0465 fax
Karen.Baranick@medconfs.com
www.medconfs.com

Course Objectives

At the end of this program, participants will be able to:

- I Discuss the newest thoughts on the role of genetics in choroidal neovascularization
- II Recall new developments in pharmacologic therapy for CNV
- III Discuss the results of the Celebrex-PDT treatment trial for neovascular AMD
- IV Recall new developments in the intraocular lymphoma
- V Discuss what is new and interesting in pediatric vitreoretinal surgery
- VI Evaluate possible solutions for the medicolegal issues surrounding screening for ROP
- VII Discuss the meaning of bradyopsia
- VIII Discuss the histopathology of ARMD
- IX Recall the current melanoma classification system
- X Apply the latest concepts and data to the management of endophthalmitis
- XI Evaluate the methods and results of lens fragment removal
- XII Assess the utility of OCT in surgical decision-making
- XIII Review the trial results of an intravitreal dexamethasone implant for ME
- XIV Evaluate anti-VEGF monotherapy and combination therapies for AMD
- XV Evaluate currently proposed prevention therapies for AMD
- XVI Recognize another unusual neuro-retinal disease entity
- XVII Evaluate 25 gauge vitrectomy
- XVIII Evaluate heroic treatment in severe diabetic macular edema
- XIX Discuss advances in the management of pediatric retinoblastoma
- XX Discuss advances in the management of malignant melanoma